HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Application of 3D QSAR CoMFA/CoMSIA and in silico docking studies on novel renin inhibitors against cardiovascular diseases.

Abstract
For the first time, a set of renin inhibitors were subjected to the 3D QSAR/CoMFA and CoMSIA studies. The utility of renin inhibitors in the treatment of cardiovascular diseases has not been fully explored yet. At the moment, aliskiren is the first and only existing renin inhibitor in the drug market. The performed 3D QSAR/CoMFA and CoMSIA in combination with docking studies included aliskiren and 37 derivatives possessing a wide variety of bioactivity. The obtained results may aid in the design of novel bioactive renin inhibitors.
AuthorsAggeliki Politi, Serdar Durdagi, Panagiota Moutevelis-Minakakis, George Kokotos, Manthos G Papadopoulos, Thomas Mavromoustakos
JournalEuropean journal of medicinal chemistry (Eur J Med Chem) Vol. 44 Issue 9 Pg. 3703-11 (Sep 2009) ISSN: 1768-3254 [Electronic] France
PMID19410337 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Enzyme Inhibitors
  • Renin
Topics
  • Binding Sites
  • Cardiovascular Diseases (drug therapy)
  • Computer Simulation
  • Drug Design
  • Enzyme Inhibitors (chemistry, pharmacology)
  • Humans
  • Models, Molecular
  • Molecular Structure
  • Protein Binding
  • Quantitative Structure-Activity Relationship
  • Renin (antagonists & inhibitors, chemistry, metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: